What Dyne Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 8 |
| Sells | 15 | 122 |
| Total trades | 17 | 136 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 10,500 | 416,500 |
| Disposed | 2,607,271 | 7,665,588 |
| Net activity | −2,596,771 | −7,249,088 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Kerr Douglas | Head of R&D and CMO | Oct 20 | Grant / award · A | +8,000 | — | — | 170,564 |
| Posner Brian S | Director | Oct 02 | Open-market buy · P | +2,500 | $16.00 | +$40K | 27,000 |
| Kerr Douglas | Chief Medical Officer | Sep 08 | Open-market sale · S | −1,290 | $18.88 | −$24.4K | 162,564 |
| Cox John | CEO & President | Sep 08 | Open-market sale · S | −5,658 | $18.88 | −$107K | 357,507 |
| Friedl-Naderer Johanna | Chief Commercial Officer | Sep 08 | Open-market sale · S | −185 | $18.88 | −$3.49K | 152,897 |
| Kerr Douglas | Chief Medical Officer | Sep 04 | Open-market sale · S | −3,745 | $24.35 | −$91.2K | 163,854 |
| Friedl-Naderer Johanna | Chief Commercial Officer | Sep 04 | Open-market sale · S | −900 | $24.35 | −$21.9K | 153,082 |
| Rhodes Jason P | Director | Aug 14 | Open-market sale · S | −322,465 | $25.00 | −$8.06M | 428,946 |
| Rhodes Jason P | Director | Aug 14 | Open-market sale · S | −478,377 | $25.00 | −$12M | 567,358 |
| Rhodes Jason P | Director | Aug 14 | Open-market sale · S | −1,359,674 | $25.00 | −$34M | 2,441,454 |
| Friedl-Naderer Johanna | Chief Commercial Officer | Aug 13 | Open-market sale · S | −226 | $26.28 | −$5.94K | 153,982 |
| Lucera Erick | Chief Financial Officer | Aug 13 | Open-market sale · S | −1,797 | $26.28 | −$47.2K | 119,766 |
| Cox John | CEO & President | Aug 13 | Open-market sale · S | −4,986 | $26.28 | −$131K | 363,165 |
| Kerr Douglas | Chief Medical Officer | Aug 13 | Open-market sale · S | −1,556 | $26.28 | −$40.9K | 167,599 |
| Rhodes Jason P | Director | Aug 13 | Open-market sale · S | −63,643 | $26.20 | −$1.67M | 751,411 |
| Rhodes Jason P | Director | Aug 13 | Open-market sale · S | −94,415 | $26.20 | −$2.47M | 1,045,735 |
| Rhodes Jason P | Director | Aug 13 | Open-market sale · S | −268,354 | $26.20 | −$7.03M | 3,801,128 |
| Kersten Dirk | Director | Jul 27 | Open-market sale · S | −5,388 | $26.04 | −$140K | 3,586,796 |
| Kersten Dirk | Director | Jul 27 | Open-market sale · S | −256,072 | $25.50 | −$6.53M | 3,592,184 |
| Rhodes Jason P | Director | Jul 07 | Open-market sale · S | −5,000 | $23.61 | −$118K | 2,962 |
Loading...